A class action lawsuit has been filed against Replimune Group, alleging the company made false or misleading statements and failed to disclose critical issues related to its Biologics License Application (BLA). The suit claims Replimune did not address FDA concerns about study design and submitted incomplete data from a small patient group, potentially leading to FDA rejection of the BLA. Investors who bought shares between October 20, 2025, and April 10, 2026, and suffered losses are encouraged to contact the law firm Holzer & Holzer. The deadline to seek lead plaintiff status is October 5, 2026.
Tesla has increased its control of the U.S. electric vehicle (EV) market to 59%, marking its highest market share since 2023. This growth highlights Tesla's strong position and continued dominance in the competitive EV industry. The increased market ...
OpenAI has called on California to enhance its AI safety legislation, SB 53, by adding stricter safeguards such as monitoring AI models during training for serious incidents and improving cybersecurity throughout development. This shift comes after O...
Hyperscale cloud companies like Amazon, Alphabet, Microsoft, and Meta are projected to spend $4.1 trillion on AI-related infrastructure from 2026 to 2028, more than triple the previous six years. UBS estimates these firms will reinvest nearly 100% of...
Four stocks from Barron's Better Bets (BBB) list currently provide 'safer' dividends with yields from $1,000 invested that exceed their share prices, fitting the 'dogcatcher' ideal. Analyst forecasts suggest these top-ten BBB Dogs could achieve an av...
Adobe's stock has fallen over 22% in the past year, trading at just 10x forward earnings, a low multiple for a software giant with $27.1 billion in annual recurring revenue. Despite record Q2 revenue growth and strong AI monetization, the stock dropp...
